Stein G E, Mummaw N, Goldstein E J, Boyko E J, Reller L B, Kurtz T O, Miller K, Cox C E
Department of Medicine, Michigan State University, East Lansing 48824.
Arch Intern Med. 1987 Oct;147(10):1760-2.
Two-hundred nine patients with symptoms of acute urinary tract infection and pyuria were randomized to 400 mg of administered norfloxacin twice daily for three days, or 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days. Therapeutic outcome was assessed five to nine days and four to six weeks after treatment. The cure rates were 71/74 (96%) with norfloxacin and 81/81 (100%) with sulfamethoxazole and trimethoprim five to nine days after treatment. Only seven patients had a recurrence at the second follow-up visit; four in the norfloxacin group and three in the sulfamethoxazole and trimethoprim group. No isolates were resistant to norfloxacin, but three Escherichia coli were resistant to sulfamethoxazole and trimethoprim. Fifteen patients in each group reported a side effect during treatment. Two patients in the norfloxacin group and four patients in the sulfamethoxazole and trimethoprim group discontinued therapy due to an adverse effect. In this multicenter study, a three-day course of norfloxacin was as effective and safe as a ten-day regimen of sulfamethoxazole and trimethoprim in the treatment of acute uncomplicated urinary tract infections.
209例有急性尿路感染症状和脓尿的患者被随机分为两组,一组每日两次服用400毫克诺氟沙星,共三天;另一组每日两次服用800毫克磺胺甲恶唑和160毫克甲氧苄啶,共十天。在治疗后5至9天以及4至6周评估治疗结果。治疗后5至9天,诺氟沙星组的治愈率为71/74(96%),磺胺甲恶唑和甲氧苄啶组的治愈率为81/81(100%)。在第二次随访时,只有7例患者复发;诺氟沙星组4例,磺胺甲恶唑和甲氧苄啶组3例。没有分离株对诺氟沙星耐药,但有3株大肠杆菌对磺胺甲恶唑和甲氧苄啶耐药。每组有15例患者在治疗期间报告了副作用。诺氟沙星组有2例患者和磺胺甲恶唑和甲氧苄啶组有4例患者因不良反应而停药。在这项多中心研究中,为期三天的诺氟沙星疗程在治疗急性单纯性尿路感染方面与为期十天的磺胺甲恶唑和甲氧苄啶疗程一样有效和安全。